Matching placebo in prefilled syringe

Phase 2

Matching placebo in prefilled syringe is one of 27 therapeutic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Asthma AcuteActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Asthma AcutePhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

26 2

Flovent

GSK

Preclinical

6 3

Spiriva

Boehringer Ingelheim

Preclinical

15 4

Aclidinium Bromide

AstraZeneca

Preclinical

21 5

Duragesic

CCephalon

Preclinical

2 6

Matching placebo in prefilled syringe

CConnect Biopharm LLC

Phase 2

1 7

Coumadin

AAbbott

Preclinical

1 8

Narcan

SScienture

Preclinical

1 9

Zoloft

VViatris Specialty LLC

Preclinical

1 10

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Asthma Acute

NCT06940141

Phase 2Active, not recruiting

Chronic Obstructive Pulmonary Disease

NCT06940154

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Active, not recruiting·CConnect Biopharm LLC·Phase 2·NCT06940154·160 enrolled

Asthma Acute1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation

Active, not recruiting·CConnect Biopharm LLC·Phase 2·NCT06940141·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Matching placebo in prefilled syringe. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Matching placebo in prefilled syringe. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Connect Biopharm LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CConnect Biopharm LLC

Matching placebo in prefilled syringe

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Asthma Acute1 trial

References

Drug Info

Quick Facts

Related News